Onconetix Inc
For the period ended Dec 31, 2023. Filed Apr 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 11, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Onconetix, Inc. | ||
| Date: April 11, 2024 | By: | /s/ Ralph Schiess |
|---|---|---|
| Ralph Schiess | ||
| Interim Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on April 11, 2024.
| Signature | Title |
|---|---|
| /s/ Ralph Schiess | Interim Chief Executive Officer |
| Ralph Schiess | |
| /s/ Bruce Harmon | Chief Financial Officer |
| Bruce Harmon | |
| /s/ James Sapirstein | Chairman of the Board and Lead Independent Director |
| James Sapirstein | |
| /s/ Thomas Meier | Director |
| Thomas Meier | |
| /s/ Timothy Ramdeen | Director |
| Timothy Ramdeen | |
| /s/ Ajit Singh | Director |
| Ajit Singh | |
| /s/ Simon Tarsh | Director |
| Simon Tarsh | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.